title: Inability of University of Wisconsin solution to reduce postoperative peritoneal adhesions in rats.
abstract: OBJECTIVE
  To examine the effect of University of Wisconsin solution (UWS) on the formation of postoperative peritoneal adhesions.
  
  
  METHODS
  Laboratory experiment.
  
  
  METHODS
  University hospital, Italy.
  
  
  METHODS
  42 Sprague-Dawley rats.
  
  
  METHODS
  A standard lesion was made consisting of serosal trauma of the caecum and a parietal peritoneal defect. Rats were randomly divided into seven groups (n = 6 each): the first group acted as controls; the second had instilled normal saline 6 ml; the third Ringer's lactate 6 ml; the fourth UWS 6 ml; the fifth normal saline 12 ml; the sixth Ringer's lactate 12 ml; and the seventh UWS 12 ml.
  
  
  METHODS
  Adhesions were scored two weeks later for extent (0 to 4) and type (0 to 4). Adhesion strength was measured by a tensiometer.
  
  
  RESULTS
  The mean (SEM) scores for extent and type of adhesions were significantly lower (p < 0.05) after instillation of Ringer's lactate 12 ml [1.0 (0.4) and 1.2 (0.4), respectively] than controls [3.5 (0.3) and 2.7 (0.2), respectively]. Adhesions were also significantly weaken (p < 0.05) [101 (33) g] than in controls [207 (6) g].
  
  
  CONCLUSIONS
  Intraperitoneal instillation of normal saline and UWS were ineffective in reducing the extent and type of adhesions. Although Ringer's lactate produced a significant reduction in severity, the effect was strongly volume related. This amount of fluid may be detrimental to a patient's postoperative course.
authors.affiliation: First Department of Surgery, Laboratorio del Castro Laurenziano, La Sapienza University School of Medicine, Rome, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Cavallari
authors.forename: A
authors.initials: A
authors.lastname: Polistena
authors.forename: A
authors.initials: A
authors.lastname: Cavallaro
mesh_terms: D000005:Abdomen / Q000601:surgery; D000241:Adenosine / Q000627:therapeutic use; D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005978:Glutathione / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D007552:Isotonic Solutions / Q000627:therapeutic use; D008297:Male; D019188:Organ Preservation Solutions / Q000627:therapeutic use*; D010532:Peritoneal Diseases / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D011887:Raffinose / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077325:Ringer's Lactate; D012720:Severity of Illness Index; D000267:Tissue Adhesions / Q000517:prevention & control*
chemical_list: D007328:Insulin; D007552:Isotonic Solutions; D019188:Organ Preservation Solutions; D000077325:Ringer's Lactate; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose